# Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

> **NCT02131480** · PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 110 (actual)

## Conditions studied

- Uterus Leiomyosarcoma
- Soft Tissue Leiomyosarcoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT02131480
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2013-01
- **Final completion:** 2016-10
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131480, "Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02131480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*